Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Result of Special Meeting

28th Mar 2013 18:09

RNS Number : 2201B
TyraTech, Inc.
28 March 2013
 



THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM JAPAN, CANADA OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.

For immediate release

28 March 2013

TYRATECH, INC.

("TyraTech" or the "Company")

Result of Special Meeting

Further to the announcement dated 18 March 2013, TyraTech, Inc. (AIM: TYR and TYRU), a natural life sciences company, is pleased to announce that at the Special Meeting held earlier today, each of the resolutions as set out in the notice of Special Meeting was duly passed. Accordingly, the Fundraising (as defined in the circular dated 18 March 2013) is now unconditional save for admission.

Accordingly, the Company has approved, subject only to Admission, the issue of 60,000,000 new common shares in the capital of the Company of $0.001 each (the "New Common Shares") at 5 pence per share to the investors participating in the Fundraising.

Separately, the Company has issued a further 600,000 new common shares of $0.001 each (the "Further New Common Shares") at 5 pence per share, as part of a pre-existing third-party consultancy agreement.

Application has been made to the London Stock Exchange for the New Common Shares and the Further New Common Shares to be admitted to trading on AIM ("Admission"). It is now expected that Admission and the commencement of dealings will take place at 8 a.m. on 3 April 2013.

 

Following Admission, the Company will have 168,776,305 common shares of $0.001 each ("Common Shares") in issue, of which 1,084,413 will continue to be held in Treasury. Therefore, the total number of voting rights in the Company will be 167,691,892 ("Total Voting Rights"). The number of restricted Common Shares trading under TIDM 'TYR' following Admission will be 141,474,936 and the number of unrestricted Common Shares trading under TIDM 'TYRU' following Admission will be 27,301,369.

 

Furthermore, following Admission, the directors of the Company will hold the following number of Common Shares:

 

 

Subscription pursuant to the Fundraise

Total Common Shares held following Admission

Resulting % of Total Voting Rights

Alan Reade

2,000,000

9,811,358

5.85%

Bruno Jactel

700,000

1,365,204

0.81%

Kevin Schultz

Nil

Nil

Nil

Barry Riley

200,000

2,455,556

1.46%

James Hills

200,000

565,500

0.34%

 

 

In addition, the directors are interested in the following options over Common Shares:

 

 

Options held over Common Shares in the Company

Option exercise price

Expiry date

Alan Reade

550,000

£0.105

4 February 2020

995,125

£0.12

20 October 2020

1,000,000

£0.06

25 April 2022

100,570

£0.12

6 March 2022

Bruno Jactel

500,000

£0.06

1 January 2023

500,000

£0.12

1 January 2023

500,000

£0.15

1 January 2023

Kevin Schultz

200,000

£0.12

20 October 2020

100,000

£0.06

25 April 2022

Barry Riley

200,000

£0.12

20 October 2020

350,000

£0.06

25 April 2022

James Hills

200,000

£0.12

20 October 2020

350,000

£0.06

25 April 2022

 

 

American Vanguard Corporation, the parent company of AMVAC Chemical Corporation and, the Company's partner in its Envance Technologies joint venture, has subscribed for 49,400,000 of the New Common Shares. Following Admission, American Vanguard Corporation will hold 29.46% of the Company's Total Voting Rights. American Vanguard Corporation also holds 10,000,000 warrants in the Company (the "Warrants"). If American Vanguard Corporation were to exercise the Warrants in full, it would hold 31.73% of the Company's Total Voting Rights on a fully diluted basis (i.e. assuming exercise in full of all outstanding options held by directors and staff and of the Warrants).

 

 

For further information please contact:

 

TyraTech Inc.Alan Reade, Executive ChairmanTel: +1 919 415 4310

 

Bruno Jactel, Chief Executive Officer

Tel: +1 919 415 4280

 

N+1 Singer, Nominated Adviser and Joint BrokerAubrey Powell / Alex WrightTel: +44 20 7496 3000

 

First Columbus LLP, Joint BrokerChris CrawfordTel: +44 20 3002 2070

 

Walbrook, Financial PR and IR

Bob Huxford / Paul Cornelius / Guy McDougall

Tel + 44 20 7933 8792

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMEAPDPAEPDEFF

Related Shares:

TyratechTyratech Com Shares
FTSE 100 Latest
Value8,809.74
Change53.53